Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TRVI 
Trevi Therapeutics Inc (TRVI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/29/2025: TRVI (5-star) is a STRONG-BUY. BUY since 9 days. Profits (10.38%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $21.22
1 Year Target Price $21.22
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 92.47% | Avg. Invested days 24 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 930.21M USD | Price to earnings Ratio - | 1Y Target Price 21.22 |
Price to earnings Ratio - | 1Y Target Price 21.22 | ||
Volume (30-day avg) 8 | Beta 0.47 | 52 Weeks Range 2.36 - 8.11 | Updated Date 07/29/2025 |
52 Weeks Range 2.36 - 8.11 | Updated Date 07/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.41% | Return on Equity (TTM) -55.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 827906419 | Price to Sales(TTM) - |
Enterprise Value 827906419 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.92 | Shares Outstanding 121755000 | Shares Floating 75150720 |
Shares Outstanding 121755000 | Shares Floating 75150720 | ||
Percent Insiders 0.75 | Percent Institutions 79.2 |
Upturn AI SWOT
Trevi Therapeutics Inc
Company Overview
History and Background
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic pruritus and other dermatologic conditions. Founded to address unmet medical needs, Trevi has primarily focused on developing Haduvio for chronic pruritus associated with prurigo nodularis.
Core Business Areas
- Pruritus Therapeutics: Develops and commercializes therapies for chronic pruritus, particularly pruritus associated with prurigo nodularis.
Leadership and Structure
Hans-Peter Loebel is the CEO. The company has a standard organizational structure for a biopharmaceutical firm, with departments dedicated to research and development, clinical operations, regulatory affairs, and commercialization planning.
Top Products and Market Share
Key Offerings
- Haduvio (oral nalbuphine ER): Haduvio is Trevi's primary product candidate, an oral extended-release formulation of nalbuphine. It is being developed for the treatment of chronic pruritus associated with prurigo nodularis. Market share data is currently unavailable as it is still in clinical trials. Competitors in pruritus treatment include Regeneron/Sanofi's Dupixent and various topical corticosteroids.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. Development of novel therapeutics requires substantial investment and carries significant risk. Demand for pruritus treatments is driven by an aging population and increased prevalence of dermatologic conditions.
Positioning
Trevi Therapeutics is positioning itself as a leader in the development of novel treatments for chronic pruritus, focusing on Haduvio as a differentiated option compared to existing therapies. Their competitive advantage lies in the potential efficacy and safety profile of Haduvio if approved.
Total Addressable Market (TAM)
The total addressable market for pruritus treatments is estimated in the billions of dollars annually. Trevi's positioning within this TAM is contingent on the successful development and commercialization of Haduvio.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach with Haduvio
- Experienced management team
- Focus on a specific unmet medical need
Weaknesses
- Reliance on a single product candidate
- Lack of approved products generating revenue
- Small company size limits resources compared to larger competitors
- Dependence on successful clinical trials and regulatory approval
Opportunities
- Successful clinical trial results and regulatory approval for Haduvio
- Expansion into other indications for Haduvio
- Partnerships with larger pharmaceutical companies
- Growing market for pruritus treatments
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from existing and emerging therapies
- Patent challenges
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- SNY
- REGN
Competitive Landscape
Trevi Therapeutics faces competition from established pharmaceutical companies with approved therapies for pruritus. Trevi's advantage lies in potentially providing an effective oral option.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been focused on progressing Haduvio through clinical trials.
Future Projections: Future growth is contingent on the successful development and commercialization of Haduvio. Analyst estimates will depend on clinical trial outcomes and regulatory prospects.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Haduvio and preparation for potential regulatory submissions.
Summary
Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on pruritus, primarily through their drug Haduvio. They are in a high-risk, high-reward scenario dependent on clinical trial outcomes and regulatory approval. The company needs to demonstrate Haduvio's efficacy and safety to compete with established therapies and secure market share. Its small size necessitates strategic partnerships to optimize their long-term success. Cash management and maintaining funding will be key to survive during clinical trials and regulatory approvals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is estimated and may not be precise. Clinical trial results can vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Trevi Therapeutics Inc
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2019-05-07 | Co-Founder, CEO, President & Director Ms. Jennifer L. Good | ||
Sector Healthcare | Industry Biotechnology | Full time employees 31 | |
Full time employees 31 | |||
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.